Nevertheless, we have conclusively demonstrated that genetic KO of USP10 or enzymatic inhibition of USP10 using a ubiquitin-binding variant decreases PI3K pathway activation in PIK3CA-mutant breast cancers. This evidence concerns the gene USP10 and breast carcinoma.